Oppenheimer raised the firm’s price target on Xylem (XYL) to $162 from $150 and keeps an Outperform rating on the shares. The firm notes shares rose 10.7% after Xylem reported Q2 adjusted EPS of $1.26 and lifted 2025 guidance ranges. Organic revenue grew 6%, highlighted by double-digit growth in M&CS. Management raised its full-year revenue outlook to $8.9B-$9.0B from $8.6B-$8.7B, with organic growth expected at +4% year-over-year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL: